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Regulators of G protein signaling (RGS) proteins com-
pose a highly diverse protein family best known for
inhibition of G protein signaling by enhancing GTP hy-
drolysis by G subunits. Little is known about the func-
tion of endogenous RGS proteins. In this study, we used
synthetic ribozymes targeted to RGS2, RGS3, RGS5, and
RGS7 to assess their function. After demonstrating the
specificity of in vitro cleavage by the RGS ribozymes, rat
aorta smooth muscle cells were used for transient trans-
fection with the RGS-specific ribozymes. RGS3 and
RGS5 ribozymes differentially enhanced carbachol- and
angiotensin II-induced MAP kinase activity, respec-
tively, whereas RGS2 and RGS7 ribozymes had no effect.
This enhancement was pertussis toxin-insensitive. Thus
RGS3 is a negative modulator of muscarinic m3 receptor
signaling, and RGS5 is a negative modulator of angio-
tensin AT1a receptor signaling through Gq/11. Also,
RGS5 ribozyme enhanced angiotensin-stimulated inosi-
tol phosphate release. These results indicate the feasi-
bility of using the ribozyme technology to determine the
functional role of endogenous RGS proteins in signaling
pathways and to define novel receptor-selective roles of
endogenous RGS3 and RGS5 in modulating MAP kinase
responses to either carbachol or angiotensin.
Heterotrimeric G protein-mediated receptor signaling path-
ways are important components of the complex biological pro-
cesses controlling cellular function. These pathways involve
the activation of G subunits by exchange of GDP for GTP,
resulting in the dissociation of G from G subunits. Both
subunits transduce signals to a variety of G protein effectors
including adenylyl cyclase, voltage-sensitive Ca2 and K
channels, phosphatidylinositol 3-kinase, phospholipases C-
and A2, cGMP phosphodiesterase, and indirectly MAP kinase1
(1, 2). The regulator of G protein signaling (RGS) proteins
makes up a highly diverse protein family best known to bind
directly G subunits in their active GTP-bound state and stim-
ulate GTP hydrolysis (GTPase-activating protein (GAP)), thus
turning off G protein signaling (3–6).
Numerous studies of the specificity between RGS proteins
and G subunits have been reported using biochemical, immu-
nochemical, and functional methods. RGS proteins are GAPs
for all G proteins (5–7). RGS2 is a strong GAP for Gq (8),
whereas RGS4 is a strong GAP for both Gq and Gi (9, 10).
RGS7, -9, and -14 have marked preference for Go over other
G subunits (10, 11). Less is known about RGS3 and RGS5.
RGS5 is a member of RGS subfamily B that includes RGS1–5,
-8, -16, and G interacting protein (12, 13) and has greatest
sequence similarity to RGS4 and RGS16. RGS5 is highly ex-
pressed in heart, skeletal muscle, and thoracic aorta (14) and
can bind to Gi1, Gi2, Gi3, Go, and Gq (15). RGS3 is a
structurally distinct member of the RGS subfamily B with a
unique long N-terminal domain. It has GAP activity for most
Gi family subunits and Gq but not for Gz, Gs, or G12 (16).
It has also been shown to bind to G11 (17).
Recent studies have identified receptor-specific effects of
RGS protein action (18–20). In co-transfection studies of gona-
dotropin-releasing hormone receptor with different RGS
cDNAs, only RGS3 expression suppressed gonadotropin-releas-
ing hormone-induced IP3 responses (18). In pancreatic acinar
cells, microinjected RGS4 selectively inhibits calcium signals
induced by muscarinic versus cholecystokinin receptors (19).
An alternatively spliced N-terminal PDZ domain of RGS12
selectively binds to the C terminus of interleukin-8 receptor-B
(20).
Even though these previous studies have provided evidence
for RGS-G and RGS receptor specificity, the functional role of
endogenous RGS proteins in cells and tissues is still not clear.
A few studies on the function of endogenous RGS proteins are
emerging. First, endogenous RGS proteins in rat superior cer-
vical ganglion neurons tonically inhibit 2-adrenergic receptor
regulation of voltage-gated N-type calcium current, as deter-
mined with an RGS-insensitive Go subunit (21). Second, in an
RGS9-1 knockout mouse, the rapid deactivation of transducin
is lost, and the recovery of rod photoresponses is greatly slowed
(22). RGS2 knockout mice exhibit an “anxious” behavioral phe-
notype and impaired immunity with reduced T cell prolifera-
tion and interleukin-2 production (23). Microinjection of anti-
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bodies to RGS12 in primary culture of dorsal root ganglion
neurons selectively slows the rate of desensitization of -ami-
nobutyric acid, type B-mediated inhibition of tyrosine-phospho-
rylated N-type calcium channels (24). Finally, stable transfec-
tion of a full-length antisense RGS3 cDNA in NIH 3T3 cells
abolishes the expression of endogenous RGS3 protein and sig-
nificantly increases MAP kinase phosphorylation induced by
endothelin-1 stimulation (17). Thus, only fragmentary informa-
tion is available on the physiological function of endogenous
RGS proteins in different cell systems.
Vascular smooth muscle participates in the normal control of
vascular tone and pathological adaptation of arteries in hyper-
tension and atherosclerosis (25) and is controlled by a number
of G protein-coupled receptor pathways. The A-10 smooth mus-
cle cell line established from rat thoracic aorta is an excellent
model cell system for studying the role of RGS proteins in
vascular smooth muscle signal transduction. It retains most of
the spectrum of biological responses found in primary vascular
smooth muscle cultures (26). A-10 cells express multiple recep-
tors that regulate intracellular Ca2 concentrations through
phospholipase C, the Na/H exchanger, and phosphorylation
of growth factor receptor-binding protein-2 in regulation of
MAP kinase activity (26–28). Thus A-10 cells contain a variety
of endogenous receptor-G protein-effector signaling pathways
that allow us to test the hypothesis that specific RGS proteins
play important roles in specific signaling pathways in a living
cell system.
To elucidate functional roles for specific endogenous RGS
proteins, we have developed a ribozyme approach to inactivate
specifically RGS protein at the mRNA level. In this study, we
have inactivated the mRNAs encoding the RGS2, RGS3, RGS5,
and RGS7 proteins in A-10 cells and primary culture of vascu-
lar smooth muscle cells. The results presented here define
specific roles of RGS3 and RGS5 in inhibiting MAP kinase
signaling by muscarinic and angiotensin receptors, respec-
tively. This receptor-selective effect of RGS protein function
provides new evidence for a unique targeting of RGS action to
specific cellular responses.
EXPERIMENTAL PROCEDURES
Ribozyme Design and Synthesis—Chimeric DNA-RNA hammerhead
ribozymes targeted against the RGS domains of rat RGS2, RGS3,
RGS5, and RGS7 mRNA were chemically synthesized and modified by
introducing two phosphorothioate linkages at the 3-end using an Ap-
plied Biosystems 394 DNA/RNA synthesizer (Applied Biosystems Inc.)
and then further purified by desilylating and desalting, as described
previously (29). The structure and sequences of targeted sites on rat
RGS ribozymes are shown in Fig. 2. Inactive control ribozymes were
prepared in the same way but by scrambling the two flanking regions
and introducing two point mutations in the catalytic core region (Fig.
2A) which have been shown previously (30) to prevent ribozyme cleav-
age activity.
In Vitro Ribozyme Cleavage—To generate in vitro RGS RNA tran-
scripts as templates, pCR2.1 plasmids containing mouse RGS3 and
RGS5 RGS cDNA were linearized with restriction enzymes (BamHI and
SpeI, respectively) and then transcribed with T7 RNA polymerase as
recommended by the supplier (Promega, Madison, WI). To perform the
in vitro cleavage experiment, the ribozyme and RGS RNA were dena-
tured separately in 50 mM Tris-HCl, pH 8.5, at 90 °C for 30 s, then
mixed in the presence of 20 mM MgCl2 (total volume of 10 l), and
incubated at 50 or 37 °C for 1 h. Two pmol of template and 100 pmol of
ribozyme were used. The reaction was stopped by the addition of 1
volume of stop solution consisting of 95% formamide and 60 mM Na-
EDTA, pH 8.0, and subjected to denaturing mini-gel electrophoresis
(5% polyacrylamide, 7 M urea) as described previously (31). Finally, the
gel was stained with ethidium bromide and photographed.
Delivery of Ribozymes into Cells—The A-10 cell line, derived from the
thoracic aorta of a DB1X embryonic rat, was obtained from the ATCC
(catalog number CRL-1476) and grown in RPMI 1640 (Invitrogen) sup-
plemented with 4 mM glutamine and 10% fetal bovine serum. The
primary culture of rat smooth muscle cells (RAOSMC) derived from the
tunica intima and inner layer of tunica media of healthy and fibrous
plaque-free rat aorta were obtained from Cell Application, Inc. (San
Diego, CA, catalog number R354-05) and grown in Rat Smooth Muscle
Cell Growth Medium (Cell Application, Inc.). Both cells were main-
tained in a 37 °C incubator with 5% CO2 in air atmosphere. A day before
transfection, cells were plated in either 100-mm dishes (for analysis of
protein suppression) or 6-well plates (for analysis of mRNA suppres-
sion, MAP kinase assay and IPx assay) and transfected at 60–80%
confluence with LipofectAMINE PLUS (Invitrogen) or Effectene trans-
fection reagent (Qiagen, for MAP kinase and IPx assay only) according
to the supplier’s manual. The amount of RGS ribozyme transfected was
4 g with 30 l of LipofectAMINE for the 100-mm dish and 1 g with
4 l of LipofectAMINE for the 6-well plate, respectively. For Effectene,
0.5 g of ribozyme and 12.5 l of Effectene transfection reagent were
used per well in 6-well plates. Sham transfection was done with either
pcDNA3.1 plasmid or inactive ribozyme as indicated. The transfection
efficiency, determined by transfection with the yellow fluorescent pro-
tein expression vector pEYFP (CLONTECH), was about 40–50% for
either Effectene or LipofectAMINE methods in both cells.
Reverse Transcription-PCR (RT-PCR)—Total RNAs were prepared
from either rat brain or A-10 cells with or without RGS-specific ri-
bozyme transfection using RNeasy Mini kit (Qiagen) and then subjected
to the RT-PCR with SuperScriptTM One-StepTM RT-PCR System ac-
cording to the supplier’s manual (Invitrogen). A negative control was
done using Ready-to-Go You-Prime First-Strand Beads (Amersham
Biosciences) in which the first step of reverse transcription was omitted
in the RT-PCR. Primer pairs generated from the RGS-coding region
TABLE I
RGS composition in A-10 cells
RT-PCR primers specific for the rat RGS subtypes (except for RGS3 and RGS7 sense primers that were from mouse sequences) were designed
to anneal to the indicated sequences. The cDNA clones used for positive controls and the size of the expected product in RT-PCR analysis are also
indicated. ND indicates not determined.
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were used to amplify each RGS as shown in Table I. Each pair of
primers was first checked by amplifying RGS plasmid DNA to make
sure that the correct size of the PCR product was achieved. For ampli-
fying RGS2, RGS3, RGS7, and RGS9 in A-10 cells, total RNA of 200–
400 ng was used with 0.3 M primer and 1.2 mM MgSO4 in a 25-l
volume. The reverse transcription was performed at 45 °C for 30 min
and followed by PCR with 35–40 cycles at 95 °C for 30 s, 45 °C for 45 s,
and 72 °C for 30 s. Different conditions were required for amplifying
RGS5; total RNA of 400–800 ng was used with 8% Me2SO and 1.8 mM
MgSO4 in a 25-l volume, and then the RT-PCR was performed for 45
cycles at 95 °C for 30 s, 50 °C for 45 s, and 72 °C for 30 s. Similar
conditions were used for amplifying RGS in RAOSMC by RT-PCR. For
amplifying muscarinic receptor mRNA, subtype-specific primers for rat
muscarinic receptors were designed as follows: m1, sense 5-GAACAC-
CTCAGTGCC-3, antisense 5-AGAGCTGCCCTTCGG-3 (product 428
bp); m2, sense 5-GGCTTGGCTATTACCAGTCC-3, antisense 5-GAG-
GATGAAGGAAAGGAC-3 (product 432 bp); m3, sense 5-CAAC-
CTCGCCTTTGTTTCC-3, antisense 5-GGACAAAGGAGATGACCC-3
(product 569 bp); m4, sense 5CTTCACGCCTGTCAATGG 3, antisense
5-CTCTTGCCCACCACAAAC-3 (product 422 bp); and m5, sense 5-
GGAAGGGGAGTCTTACAATG-3, antisense 5-GGAACTGGATCTG-
GCACTC-3(product 556 bp). For RT-PCR of muscarinic receptors, 50
ng of total RNA from either rat brain or A-10 cells was amplified at
95 °C for 30 s, 50 °C for 45 s, and 72 °C for 40 s for 30 cycles in a 12.5-l
volume. Elongation factor 1 was amplified under identical condition as
an internal control. The RT-PCR products were electrophoresed on a
1.8% agarose gel, stained with ethidium bromide stimulated with a
Kodak ImageStation, and photographed. The intensity of the bands was
quantified by densitometry analysis using the Kodak One-dimensional
3.5 software.
Western Blot for RGS3 Protein—Of the RGS proteins detected at the
mRNA level in A-10 cells (RGS2, -3, -5, and -7), only RGS3, -7, and -9
antibodies were useful for Western blotting. Whole cell lysates were
prepared from A-10 cells transfected with or without RGS ribozyme by
suspending them in RIPA lysis buffer containing 1 phosphate-buff-
ered saline, 1% Igepal CA-630 (Sigma), 0.5% sodium deoxycholate, 0.1%
SDS with fresh addition of 0.15–0.3 TIU/ml aprotinin (Sigma), 1 mM
sodium orthovanadate, 1 mM benzamidine, 1 g/ml pepstatin, and 2
g/ml leupeptin. Cells were passed 10 times through a 21-gauge needle;
10 g/ml phenylmethylsulfonyl fluoride was added, and the mixture
was incubated for another 1 h on ice and finally centrifuged at 10,000 
g for 10 min. The supernatant was saved as total cell lysate. Protein
(60–100 g) was subjected to SDS-PAGE on an 8% mini-gel and trans-
ferred to ImmobilonTM-P transfer membrane. The membrane was
blocked with 3% milk in TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl)
without Tween 20 for 1 h and incubated with 1:200 anti-RGS3 antibody
(Santa Cruz Biotechnology, sc-9304) overnight in the cold room. For
screening RGS7 and RGS9 proteins, antibodies kindly supplied by Drs.
Theodore Wensel (Baylor College of Medicine, Houston, TX) and
Vladlen Slepak (University of Miami School of Medicine, FL) were used
at 1:1,000 to 1:2,000 dilution for 1 h at room temperature. After three
consecutive washes with TBS plus 0.05% Tween 20 (10 min for each),
the membrane was incubated with 1:10,000 secondary antibody (anti-
rabbit horseradish peroxidase linked F(ab)2 fragment from donkey,
Amersham Biosciences, catalog number NA 9340) for 1 h at room
temperature. Prestained SDS-PAGE protein standards (Bio-Rad, cata-
log number 161-0309) were used to determine the size of detected
proteins. For RGS3 samples, the blots were re-blotted with anti-G
protein -subunit antibody (Santa Cruz Biotechnology, sc-378) at
1:20,000 dilution after stripping as an internal control for the determi-
nation of protein loading. Proteins were visualized by chemilumines-
cence with SuperSignal West Dura (Pierce). The intensity of bands was
quantified by densitometry analysis of films in the linear range of
exposure using a Hewlett-Packard ScanJet scanner.
MAP Kinase Assay—A day before transfection, cells were plated into
6-well plates and transfected with either inactive or RGS-specific ri-
bozymes with the Effectene transfection reagent (Qiagen). Thirty hours
after transfection, cells were put into serum-free medium and then at
72 h post-transfection were washed with phosphate-buffered saline and
stimulated with the appropriate agonist for 5 min, and finally har-
vested by addition of 250 l of Stopping Buffer containing 1 Protein
Loading Buffer with 50 mM dithiothreitol, 1 mM sodium orthovanadate,
10 mM sodium fluoride, 0.15–0.3 TIU/ml aprotinin (Sigma), 2 g/ml
leupeptin, and 1 mM EDTA, pH 8.0. For RAOSMC, cells were starved
for 48 h and lysed with 100 l/well 1 SDS Sample Buffer containing
62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol,
0.01% bromphenol blue and immediately scraped off the plate. Then
samples were heated at 95 °C for 5 min and cooled on ice. Finally, the
lysates were subjected to 12% SDS-PAGE and transferred to Immo-
bilonTM-P transfer membrane for Western blotting. For A-10 cells, the
blot was first probed with phospho-ERK antibody (1:500, Santa Cruz
Biotechnology, sc-7383) to measure the activated phospho-ERK and
visualized by chemiluminescence with SuperSignal West Dura (Pierce).
Generally, only a single band at 42 kDa corresponding to phospho-
ERK2 was observed in the A-10 cells. Some experiments showed a faint
signal at 44 kDa corresponding to ERK1, but only the ERK2 results
could be analyzed. The same blot was stripped and re-blotted with
anti-ERK-2 which is reactive with ERK2 p42 and to a lesser extent with
ERK1 p44 (1:1000, Santa Cruz Biotechnology, sc-153) to measure total
ERK2 levels. MAP kinase activity was expressed as normalized arbi-
trary units (a.u.) of phosphorylated p42 MAP kinase (ERK2) over total
ERK2 by densitometry analysis of films in the linear range of exposure
using a Hewlett-Packard ScanJet scanner. For RAOSMC, the blot was
first probed with Phospho-p44/42 MAPK (Thr-202/Tyr-204) E10 mono-
clonal antibody (1:1000, Cell Signaling Technology, catalog number
9106) to measure the activated phospho-ERK and visualized by chemi-
luminescence with SuperSignal (Pierce). Both p44 and p42 bands cor-
responding to phospho-ERK1/2 were observed in RAOSMC cells. The
same blot was stripped and re-blotted with anti-ERK-2 (1:1000, Santa
Cruz Biotechnology, sc-153) to measure total ERK levels. MAP kinase
activity was expressed as normalized a.u. of phosphorylated p42/44
ERK over total ERK by densitometry analysis of films in the linear
range of exposure using a Hewlett-Packard ScanJet scanner. Statistical
analysis was done by using one- and two-way analysis of variance in
Prism (GraphPad software, version 3.01) with Tukey’s Multiple Com-
parison post-test to identify specific effects of the ribozymes.
Phosphoinositide Production—Measurment of inositol phosphates
(IPx including inositol monophosphate, inositol bisphosphate, and ino-
sitol triphosphates) was done as described previously (32, 33). Briefly,
RAOSMC cells were transfected with ribozymes as done for the MAP
kinase assay. At 48 h post-transfection, cells were incubated with
[3H]myoinositol (10 Ci/ml/dish) for another 24 h at 37 °C in Dulbecco’s
modified Eagle’s medium without inositol. Labeling was terminated by
aspirating the medium and rinsing cells with oxygenated reaction
buffer containing 142 mM NaCl, 30 mM Hepes buffer, pH 7.4, 5.6 mM
KCl, 3.6 mM NaHCO3, 2.2 mM CaCl2, 1.0 mM MgCl2, 10 mM LiCl, and 1
mg/ml D-glucose. The stimulation of IPx production was initiated by
incubating cells with different concentrations of AngII in 0.5 ml of
reaction buffer for 30 min at 37 °C. Then the reaction was stopped by
adding 0.5 ml of ice-cold 20% trichloroacetic acid, and samples were
kept on ice for another 30 min. Cells were scraped, and precipitates
were pelleted (4100  g, 20 min). The trichloroacetic acid-soluble frac-
tion was transferred to a new tube, extracted with water-saturated
diethyl ether three times, and then neutralized with NaHCO3. Finally,
IPx was isolated by adsorption to 0.5 ml of 50% (w/w) Dowex AG 1-X8
formate resin slurry and rinsed with unlabeled 5 mM myoinositol three
times, followed by elution with 1 ml of 1.2 M ammonium formate and 0.1
M formic acid. The elutes were counted by liquid scintillation counter in
10 ml of ScintiVerse.
Whole Cell [125I]AngII Binding Assay—A-10 or RAOSMC cells were
transfected using the same conditions as for the MAPK assays and
rinsed with 1 ml of assay buffer containing 0.1% bovine serum albumin
(Sigma catalog number A-6003) and 0.1 mg/ml bacitracin in Opti-MEM
medium. Then cells were incubated with 100 pM [125I-Tyr4]angiotensin
II (human, 2200 Ci/mmol, PerkinElmer Life Sciences, catalog number
NEX105) in the assay buffer for 1 h at room temperature. For nonspe-
cific binding, separate dishes were incubated with the same hot buffer
plus 10 M saralasin (Sigma catalog number A-2275). After incubation,
cells were washed three times with assay buffer and precipitated with
ice-cold 5% trichloroacetic acid for another 30 min in the cold room.
Finally, the supernatant was aspirated and counted by liquid scintilla-
tion counter in 10 ml of ScintiVerse. Nonspecific binding represented
0.3% of total binding.
RESULTS
Expression of RGS in A-10 Cells—Consistent with the known
variety of endogenous receptor-G protein-effector pathways in
A-10 cells, we have identified a number of RGS proteins that
are expressed at both the mRNA and the protein levels in these
cells. Previous studies have shown that RGS2, -3, and -10–12
and G interacting protein mRNA are present in primary cul-
tures of rat vascular smooth muscle cells (34) and RGS1, -3–7,
-9, -12, -14, and -16 are detectable in cardiomyocytes (35).
Accordingly, we tested eight RGS genes for expression in A-10
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cells by RT-PCR. Five (RGS2, -3, -5, -7, and -9) of the eight
tested RGSs were detected strongly at the mRNA level by
RT-PCR (Fig. 1). RGS11 was weakly detected (data not shown),
and RGS4 and RGS6 were not detectable. Positive control
cDNA clones for all eight were readily amplified indicating
correct choice of primers. At the protein level, only a few anti-
RGS antibodies were tested due to the limited availability of
good quality anti-RGS-specific antibodies. An RGS3 antibody
detected a doublet at 60 kDa in A-10 cells consistent with the
predicted size of 61.5 kDa for mouse RGS3 (GenBankTM acces-
sion number AF215670). RGS9 antibody detected a strong dou-
blet at 72 kDa consistent with the 77-kDa predicted molecu-
lar mass for the long splice variant of RGS9 (data not shown).
RGS7 antibody did not detect a signal in A-10 cells under
current conditions but did detect a very strong band at 55
kDa in a rat brain lysate positive control (data not shown).
Thus RGS7 while showing abundant mRNA levels did not show
detectable protein expression. Thus, we were able to confirm
protein expression of RGS3 and RGS9 but not RGS7, whereas
RGS2 and RGS5 could not be tested due to the unavailability of
antibodies. This varied complement of RGS expression in A-10
cells allowed us to test directly the hypothesis that endogenous
RGS proteins contribute to the specificity and regulation of
receptor signaling in vascular smooth muscle.
Design and Synthesis of Rat RGS-specific DNA-RNA Chi-
meric Hammerhead Ribozymes—To determine the functional
role of the endogenous RGS proteins, we designed hammerhead
ribozymes that were targeted to a GUC sequence encoding the
RGS domain within RGS2, -3, -5, and -7 mRNA. The “GUC”
cleavage sites in the RGS domain were chosen because the RGS
domain is a known functional region of RGS proteins. Several
GUC sequences were present in each RGS mRNA, so selection
of gene-specific target sites was done by manually searching for
a unique nucleotide composition of the flanking region as
shown in Fig. 2B. Because this study was ultimately aimed at
using ribozymes in cell systems, the RGS ribozymes were
chemically synthesized as a chimeric DNA-RNA construct to
improve their resistance to intracellular endonucleases. The
chimeric DNA-RNA ribozyme (Fig. 2A) consisted of a catalytic
core containing ribonucleotides (in lowercase letters) and flank-
ing sequences containing deoxyribonucleotides (in capital let-
ters), which hybridize specifically to the targeted RGS mRNA
transcript by Watson-Crick base pairing. In addition, two phos-
phorothioate linkages were added to the 3-end of the ribozyme
to improve the stability and cellular delivery of the ribozymes
as shown previously (29).
Catalytic Activity of RGS Ribozyme in Vitro—To confirm that
the RGS ribozymes were capable of cleaving the targeted RNA,
the catalytic activity of RGS ribozymes was examined using
RGS RNA transcribed in vitro. As shown in Fig. 2C, RGS5 RNA
synthesized from a mouse RGS5 cDNA clone generated a prod-
uct of 720 bases that includes the entire 546 bases of RGS5
coding region sequence, 77 bases of 3-untranslated sequence,
FIG. 1. Expression of RGS mRNAs in A-10 cells. Total RNA pre-
pared from A-10 cells was subjected to RT-PCR (lane A) using RGS-
specific primers (Table I) that were tested by amplifying RGS cDNA
plasmids (lane B) as a positive control. The PCR products were sepa-
rated on a 1.8% agarose gel, stained with ethidium bromide, and pho-
tographed. The expected sizes of PCR products are shown in Table I. NC
indicates the negative control in which the reverse transcriptase was
omitted before PCR amplification with RGS3 primers.
FIG. 2. Sequence, structure, and in vitro cleavage of rat RGS-
specific hammerhead ribozymes. A, the targeted RGS5 mRNA tran-
script is shown in the 5 to 3 direction (upper sequence). The con-
structed DNA-RNA chimeric hammerhead ribozyme is shown in the
complementary 3 to 5 direction (lower sequence). The targeted GUC
trinucleotide in the RGS mRNA is underlined, and the cleavage site is
indicated by the arrow. The ribonucleotides of the ribozyme required for
catalytic activity in the core region are shown in lowercase letters, and
the complementary flanking regions of deoxyribonucleotides are shown
in capital letters. The positions of the two phosphorothioate linkages at
the 3-terminal region of the ribozyme, added to enhance stability, are
indicated by asterisks. The nucleotides and arrows in the catalytic core
region indicate changes to generate the inactive ribozymes. B shows the
targeting site in the RGS domain for the four rat RGS-specific ri-
bozymes. C, in vitro cleavage of RGS5 mRNA transcripts by the RGS5
ribozyme. The chemically synthesized RGS5 ribozyme and RGS5
mRNA transcript (50:1 ratio) were incubated together for 15 or 60 min
and then the cleavage products were separated on a 5% polyacrylamide,
7 M urea gel, visualized by ethidium bromide staining, and photo-
graphed. The full-length RGS5 transcripts (720 bp) were cleaved into
two small fragments (385 and 335 bp) at 50 °C. The RGS5 ribozyme also
showed good cleavage activity in 60 min at physiological temperatures
(37 °C).
Receptor-selective Regulation of MAP Kinase by RGS3 and RGS524952
and 71 bases of 5- and 26 bases of 3-multicloning regions of
pCR2.1 vector. Mouse RGS5 is 94% identical to the rat RGS5
cDNA at the nucleotide level and 100% identical over the RGS5
ribozyme flanking regions. Addition of the RGS5 ribozyme to
the RGS5 RNA transcript generated two expected fragments of
385 and 335 bases corresponding to cleavage at the targeted
GUC site. Thus the ribozyme-mediated cleavage of the RGS5
RNA transcript was site-specific. Furthermore, over 90% of the
template was cleaved in 1 h at 37 °C indicating that this RGS5
ribozyme is capable of disrupting the RGS5 mRNA at a
physiological temperature. Similar results were obtained
with the RGS3 ribozyme (not shown). These results indicate
that the designed RGS ribozymes are capable of efficiently
cleaving the targeted mRNA in a site-specific fashion.
Effect of RGS Ribozymes on RGS mRNA in Cells—To exam-
ine the activity of the RGS ribozymes in intact cells, they were
introduced into rat A-10 cells by transient transfection with
LipofectAMINE PLUS. At 48 h post-transfection, total RNA
was extracted from cells transfected with or without the des-
ignated RGS ribozyme, and the level of RGS mRNA was deter-
mined by RT-PCR. As shown in Fig. 3A, the level of each RGS
mRNA (i.e. RGS2, -3, -5, and -7) was decreased by its own
RGS-specific ribozyme compared with the control without ri-
bozyme (i.e. sham-transfected with pcDNA3.1 vector). The con-
trol elongation factor 1 transcript was unaffected by ri-
bozymes in each case. To test the time course of ribozyme
effects, RGS3 mRNA expression was determined at 24, 48, and
72 h post-transfection with RGS3 ribozyme. The level of RGS3
mRNA was reduced to 57  1.4, 60  9.1, and 51  20% (n 
3) of the control level determined without RGS3 ribozyme
transfection (Fig. 3B). To establish that the specificity of RNA
cleavage was maintained upon delivery of the RGS ribozyme
into cells, we examined the effect of transfection with RGS3
ribozyme on the level of other RGS mRNAs. As shown in Fig.
3C, transfection of A-10 cells with RGS3 ribozyme did not
reduce the level of the elongation factor 1 mRNA or that of
any of the other RGS mRNAs (RGS2, RGS5, RGS7, and RGS9)
tested. In these same cells, the level of the RGS3 mRNA was
reduced to 60  1.9% (n  3) of its control value. Transfection
of an inactive control RGS3 ribozyme (RZ3m, Fig. 2) did not
reduce the level of RGS3 RNA (data not shown). These data
clearly demonstrate the cleavage activity and specificity of the
synthetic hammerhead RGS ribozymes for the targeted RGS
RNA when delivered into intact cells by transfection. Given the
fact that the transfection efficiency in A-10 cells determined
from yellow fluorescent protein expression was about 40–50%,
the 40–50% reduction of RNA level most likely represents a
nearly complete suppression in the transfected cell population.
Effect of RGS3 Ribozyme on the Level of RGS3 Protein in
A-10 Cells—Next, we investigated whether the suppression in
RGS3 RNA was paralleled by a similar reduction in the amount
of RGS3 protein in cells transfected with the RGS3 ribozyme.
For this purpose, A-10 cells were transfected with either no
ribozyme (i.e. sham-transfected with pCDNA3.1 vector) or
RGS3 ribozyme and harvested at 72 h post-transfection. Whole
cell lysates were prepared from these cells and evaluated by
immunoblotting with anti-RGS3 antibody. Fig. 4A shows a
representative immunoblot probed with anti-RGS3 antibody
and then probed with an anti-G antibody as a loading control.
G antibody alone showed a single band at 35 kDa, and the
amount of G protein  subunit was not changed by RGS3
ribozyme transfection. The RGS3 antibody detected a doublet
band of 60 kDa in control cells that was clearly reduced in the
cells transfected with the RGS3 ribozyme. Fig. 4B shows a
quantitative analysis of these results in which the relative
amounts of RGS3 protein and G were quantified and ex-
pressed as a percentage of the control level. RGS3 protein was
suppressed to 45  1% of the control value in ribozyme-treated
cells, whereas the level of G in ribozyme-treated cells was
107  6% of control. Thus the RGS3 ribozyme suppresses RGS3
protein levels as well as mRNA levels.
Differential Effects of RGS3 and RGS5 Ribozymes in En-
hancing Carbachol- and Angiotensin II-stimulated MAP Ki-
nase Activity—It was previously shown that RGS3 and other
members of the RGS family can inhibit G protein-stimulated
MAP kinase activation when transfected into cells either tran-
FIG. 3. Suppression of endogenous RGS mRNA expression in
RGS ribozyme-transfected A-10 cells. A, effect of RGS ribozyme
cleavage on RGS mRNA level in A-10 cells. Total RNAs were prepared
from plasmid control () and RGS ribozyme-transfected () A-10 cells
at 48 h after transfection, and the levels of RGS mRNA transcripts were
quantified by RT-PCR analysis. RT-PCR was done under the same PCR
conditions for RGS3, RGS2, RGS7, and RGS9. RGS5 required a modi-
fied RT-PCR protocol (see “Experimental Procedures”). A control
mRNA, elongation factor 1 (EF-1), was tested using the same RT-
PCR conditions as used for the RGS being studied. PCR products were
separated on a 1.8% agarose gel and visualized by ethidium bromide
staining. The expected sizes of PCR product are indicated in Table I.
EF-1 in each set showed very similar intensity with or without RGS
ribozyme treatment, whereas the RGS mRNA was suppressed only in
the cells treated with that RGS-specific ribozyme (arrowheads). B, time
course of RGS3 mRNA suppression by RGS3 ribozyme treatment in
A-10 cells. Total RNA was prepared from control (pCDNA3.1, ) and
active RGS3 ribozyme-transfected (RZ3) A-10 cells at 24, 48, and 72 h
post-transfection, and the levels of RGS3 mRNA were quantified by
RT-PCR analysis. Data represent mean  S.E. from three experiments.
C, gene specificity of RGS3 ribozyme suppression at mRNA level in A-10
cells. Total RNA was prepared from control (pCDNA3.1, ) and RGS3
ribozyme-transfected A-10 cells (RZ3) at 48 h post-transfection, and
the levels of different RGS mRNA transcript were quantified by RT-
PCR analysis. Data are mean  S.E. of three determinations.
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siently (36, 37) or in a stable manner (17). Because overexpres-
sion can elicit effects that do not occur at normal protein levels,
we wanted to determine whether any endogenous RGSs influ-
ence MAP kinase activity in A-10 cells stimulated by an endog-
enous receptor. A-10 cells were transiently transfected with
inactive RGS3 ribozyme or a panel of active RGS ribozymes,
and then carbachol-induced activation of MAP kinase was de-
termined by Western blotting with a phospho-specific ERK
antibody (Fig. 5, A and C). ERK phosphorylation was expressed
as a ratio (normalized arbitrary units) of phosphorylated p42
MAP kinase (ERK2) divided by total ERK2 as determined by
densitometry analysis. Through endogenous receptors, carba-
chol alone caused only a 31% increase in phospho-ERK levels
(96 versus 65 a.u.). This was blocked by 1 M atropine indicat-
ing a muscarinic cholinergic mechanism (data not shown).
None of the RGS ribozymes caused a significant increase in
phospho-ERK levels in the absence of agonist (Fig. 5C). Only
the RGS3 ribozyme significantly enhanced carbachol-stimu-
lated MAP kinase activity (Fig. 5C, Carb/RZ3, 139  9, versus
Carb/RZ3m, 96  8 a.u., p  0.01). This represents a 43%
increase compared with the inactive control RGS3 ribozyme
(RZ3m). The other RGS ribozymes had no effect on carbachol-
stimulated MAP kinase activity. Thus endogenous RGS3 ap-
pears to be a negative modulator of MAP kinase activity in
muscarinic receptor signaling in A-10 cells.
Next, we investigated whether any endogenous RGSs would
influence MAP kinase activity stimulated by angiotensin in
A-10 cells. Because the AT1a receptor is not expressed in A-10
cells, we co-transfected the rat AT1a receptor together with the
same panel of RGS-specific ribozymes used above or the inac-
tive RGS5 ribozyme (RZ5m) as a control. Angiotensin II (AngII)
induced phosphorylation and activation of MAP kinase was
again determined by Western blotting with the phospho-ERK
antibody at 72 h post-transfection. As with carbachol, AngII
alone caused only a small increase of 28% in phospho-ERK
levels compared with nonstimulated controls (87  7 versus
67  2, Fig. 5, B and D). Surprisingly, the RGS5 ribozyme but
not the RGS3 ribozyme enhanced AngII-stimulated MAP ki-
nase activity. RGS5 ribozyme caused a 64% increase (Fig. 5D,
AngII/RZ5, 141  14, versus AngII/RZm5, 86  7, p  0.005)
compared with AngII with the inactive RGS5 ribozyme
(RZ5m). The other RGS ribozymes had no effect on AngII-
stimulated MAP kinase activity. To rule out an effect of the
RGS5 ribozyme on receptor expression in A-10 cells, 125I-AngII
binding to intact cells was measured under the transfection
conditions identical to those for MAPK assays. Results from the
triplicate measurements expressed as a percentage of the
RZ5m data were as follows: RZ5m 100%, RZ5 108  0.008%,
and RZ3 108  0.02%. So ribozyme transfection did not alter
signaling via an effect on receptor expression. These data dem-
onstrate a differential effect of endogenous RGS3 and RGS5 on
MAP kinase activity induced by endogenous muscarinic recep-
tor and exogenous AT1a receptors in A-10 cells. We thus pro-
vide novel evidence of receptor specificity of the effects of en-
dogenous RGS3 and RGS5 protein in this vascular smooth
muscle cell line.
PTX Insensitivity of RGS3 and RGS5 Ribozyme-enhanced
MAP Kinase Activity—The RGS specificity observed in Fig. 5
could result from different G proteins mediating receptor cou-
pling to MAP kinase activation (i.e. Gq or Gi family). We there-
fore wanted to determine whether the enhancement of MAP
kinase activity by RGS3 and RGS5 ribozymes was sensitive to
pertussis toxin (PTX). Accordingly, A-10 cells were transfected
with active RGS3 or RGS5 ribozyme or the corresponding in-
active control ribozyme and then treated with or without per-
tussis toxin overnight. Agonist-induced MAP kinase activity
was measured with or without carbachol or AngII stimulation.
Both carbachol (Fig. 6A) and AngII (Fig. 6B) still stimulated
MAP kinase activity, and this stimulation was still enhanced
by the RGS3 ribozyme or RGS5 ribozyme, respectively, even
after PTX pretreatment. Maximal values for phospho-ERK
with agonist stimulation plus RGS ribozyme were 186  7 (n 
5) for Carb/RZ3 and 162  2 (n  3) for AngII/RZ5. The
maximal agonist/RZ effects with PTX were similar to those
without PTX (201  10, n  3, for Carb/RZ3; 154  19, n  6,
for AngII/RZ5). The inability of PTX to reduce ribozyme-en-
hanced MAP kinase activity indicates that both carbachol and
AngII responses are mediated through a non-Gi/o signaling
mechanism, most likely through a Gq/11 family G protein. Thus
the differences between effects of RGS3 and RGS5 protein on
carbachol and AngII stimulation do not appear to result from
differential G protein coupling (Gi versus Gq), as both receptor
systems are likely using Gq family proteins (see “Discussion”).
Characterization of Muscarinic Receptor Subtypes in A-10
Cells—There are five subtypes (m1, m2, m3, m4, and m5) of
muscarinic receptors with the “odd-numbered” muscarinic re-
ceptor (m1, m3, and m5) subtypes typically coupled via the
PTX-insensitive Gq/11 family, whereas the “even-numbered”
members (m2 and m4) generally activate PTX-sensitive Gi/Go
(38). RGS3 ribozyme enhancement of carbachol-stimulated
phospho-ERK activity was not abolished by PTX pretreatment
(Fig. 6A) suggesting the involvement of muscarinic receptor
subtypes m1, m3, or m5 in this signaling pathway. To charac-
FIG. 4. Suppression of endogenous RGS3 protein expression in
RGS3 ribozyme-transfected A-10 cells. A, Western blot of RGS3
protein. Whole cell lysates were prepared from A-10 cells 72 h after
transfection with (RZ3) or without (pCDNA3.1, ) RGS3 ribozyme
and resolved on 8% SDS-PAGE for Western blot analysis as described
under “Experimental Procedures.” The anti-RGS3 antibody detected a
doublet of about 60 kDa and anti-G protein -subunit antibody (G) was
used as an internal control for the determination of equal protein
loading. B, quantitative analysis of RGS3 and G expression in ri-
bozyme-treated samples, presented as mean  S.E. of percent of control
from three experiments similar to that shown in A.
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terize further the muscarinic receptor subtypes in A-10 cells,
specific primers were designed to amplify each muscarinic re-
ceptor subtype by RT-PCR from total RNA prepared from rat
brain (as positive control) or from A-10 cells. As shown in Fig.
7, all five subtypes were easily detected in rat brain mRNA, but
only m3 was strongly detected in A-10 cells. m4 was detectable,
and m1 showed a very weak band. Thus an endogenous m3
subtype of muscarinic receptor seems to be involved in RGS3
ribozyme-enhanced MAP kinase activation.
RGS5 Ribozyme Enhances Angiotensin II-stimulated MAP
Kinase and IPx Accumulation through Endogenous AT1a Re-
ceptors in Primary Cultures of Aortic Smooth Muscle—In an
effort to show a more robust effect of RGS knockdown on Erk
activation and to assess effects on an endogenous AT1aR, we
turned to primary cultures of RAOSMC. These cells express
high levels of endogenous angiotensin AT1a receptor. Further-
more, the mRNAs for RGS2–7 and -11 but not -9 were detect-
able by RT-PCR (data not shown). As shown in Fig. 8, 1 nM
AngII produces a significant stimulation of ERK1/2 phospho-
rylation (3.3  0.5- and 2.9  0.8-fold for the control inactive
ribozymes RZ5m and RZ3m). Transient transfection of the
active RGS5 ribozyme (RZ5) dramatically increased AngII-
stimulated phosphorylation of ERK1/2 (to 6.2  1.9-fold). On
the other hand, the RGS3 ribozyme (RZ3) had no effect (AngII
stimulation of 3.2  1.4-fold). Preliminary studies also showed
no effect of RGS2 or RGS7 ribozymes in RAOSMC cells. With
higher doses of AngII stimulation (e.g. 10 nM), there was no
difference between the different transfected ribozyme in en-
hancing ERK1/2 activation (data not shown). This effect to
enhance the sensitivity of receptor responses but not the max-
imum effect is similar to that seen in the sst2-deleted strains of
Saccharomyces cerevisiae (39) and for adrenergic regulation of
ion channels by RGS-resistant Go subunits (21). These results
show a more robust effect of RGS5 ribozyme and confirm the
lack of effect of RGS3 ribozyme on AngII-stimulated phospho-
rylation of ERK. To rule out that the effects of RGS5-specific
ribozyme on ERK activation is due to an increase in receptor
expression in RAOSMC cells, 125I-AngII whole cell binding was
measured. Results expressed as a percentage of RZ5m from the
average of duplicates were as follows: RZ5m 100%, RZ3m
101  0.02%, RZ2 104  0.04%, RZ3 106  0.03%, RZ5 106 
0.004%, and RZ7 106  0.02%. Because the same specificity is
seen in A-10 cells with transfected AT1aR and for the endog-
enously expressed AT1aR in primary cultures, it is likely that
RGS5 plays an important role in regulation of angiotensin
signaling in vascular smooth muscle in vivo.
To look at the effects of endogenous RGS on upstream com-
ponents of angiotensin signaling pathways, we assessed inosi-
tol phosphates (IPx) release in RAOSMC. As shown in Fig. 9,
transient transfection of RGS5 ribozyme (RZ5) enhanced IPx
accumulation by the lowest doses (1–3 nM) of AngII compared
with the control cells transfected with inactive ribozyme
(RZ5m). Also, the RGS3 ribozyme had no effect on AngII-
stimulated IPx accumulation. At the higher doses of AngII
(10–100 nM), RZ5 had no effect on IPx accumulation. That the
IPx signal in RGS5 ribozyme-treated cells is lower at high (10
nM) but not low (1–3 nM) AngII concentrations might be due to
fast desensitization of angiotensin receptor, especially with
FIG. 5. Differential effects of RGS3 and RGS5 ribozymes in enhancing carbachol- and angiotensin II-stimulated MAP kinase
activity. A and C, A-10 cells were transfected with the inactive RGS3 ribozyme (RZ3m) or with the panel of RGS-specific ribozymes (RZ2, RZ3,
RZ5, or RZ7). After 30 h, serum was removed from the medium and at 72 h post-transfection, A-10 cells were stimulated with 200 M carbachol
for 5 min, harvested, and subjected to 12% SDS-PAGE for MAP kinase analysis by Western blot using ERK-2 and phospho-ERK antibodies as
described under “Experimental Procedures.” A is a representative Western blot and the C shows the mean  S.E. of five independent experiments.
The asterisk indicates that RGS3 ribozyme produced a statistically significant (p  0.01) enhancement of carbachol-stimulated MAP kinase activity
(Carb, black bar) compared with carbachol plus the inactive RGS3 ribozyme (Carb, , white bar). B and D, A-10 cells were co-transfected with the
AT1a receptor plasmid plus either the inactive RGS5 ribozyme (RZ5m) or the same panel of four RGS-specific ribozymes and then serum-starved
for 40 h prior to stimulation with 20 M AngII for 5 min at 72 h post-transfection. Cells were harvested, subjected to SDS-PAGE, and analyzed
by Western blotting. B is a representative Western blot, and the D shows mean  S.E. values from three independent experiments. ** indicates
a p value 0.003.
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higher doses. These results further confirm the selectivity of
RGS5 ribozyme for AT1aR responses and indicate that RGS5 is
likely working on Gq to regulate AT1a receptor signaling.
DISCUSSION
In this study, we have used ribozyme technology to specifi-
cally suppress the expression of different RGS proteins in a rat
aorta smooth muscle cell line (A-10 cells) and primary cultures
of RAOSMC. Two major conclusions can be derived from this
study. 1) Ribozymes can be easily designed to selectively sup-
press the expression of particular RGS at both the mRNA and
protein levels. 2) Ribozyme-mediated suppression of RGS3 and
RGS5 differentially enhances MAP kinase activity stimulated
by carbachol and angiotensin II, respectively, providing novel
evidence of receptor specificity of the actions of endogenous
RGS3 and RGS5 protein in vascular smooth muscle cells.
Ribozymes as Tool for Studying Protein Families—There are
a number of methods that can be used to assess the function of
endogenous proteins such as those in the RGS family. Neutral-
izing antibodies have been used but are mainly applicable to
electrophysiological studies because the pipette provides access
to the intracellular space (24). RGS-inhibiting drugs would be
useful (40) but are not yet available, certainly not with the
potency or specificity required for use in defining the functions
of individual RGS proteins. Thus reverse genetics approaches
to suppress expression of endogenous RGS protein remain the
best choice. There are now several such approaches as follows:
antisense (either oligonucleotides or expressed reversed full-
length constructs), ribozymes, or the recently described double-
stranded RNA interference (“RNAi”) method (41). To date,
there are only two published reports applying these approaches
to RGS proteins. These studies (17, 42) used antisense oligos
and full-length antisense expression constructs to reduce ex-
pression of RGS9 and RGS3, respectively. Ribozymes, anti-
sense oligos, and RNAi all utilize small recognition sequences
(e.g. 15–25 bp) but require introduction into the cell. Ribozymes
have two potential advantages over RNAi and antisense oligos.
First, they act catalytically as site-specific ribonucleases, re-
sulting in degradation of the targeted RNA. Second, in addition
to the complementarity between the ribozyme and flanking
FIG. 6. PTX insensitivity of RGS3 and RGS5 ribozyme-en-
hanced MAP kinase activity. A, A-10 cells transfected with the
inactive RGS3 ribozyme (RZ3m) or RGS3 ribozyme (RZ3) were serum-
starved for 40 h as described in Fig. 5. Cultures were treated with
(PTX) or without (PTX) 30 ng/ml pertussis toxin overnight prior to
stimulation with 200 M carbachol (Carb) or control with medium (C)
for 5 min, and lysates were prepared for Western blot analysis of ERK
phosphorylation. Data represent the mean  S.E. of three independent
experiments. B, A-10 cells were transfected with angiotensin AT1a
receptor plasmid plus the inactive RGS5 ribozyme (RZ5m) or active
RGS5 ribozyme (RZ5). Cells were starved for 40 h and pretreated with
(PTX) or without (PTX) 30 ng/ml PTX overnight. At 72 h post-
transfection, cells were stimulated with (AngII) or without (C) AngII (20
M) for 5 min and harvested for Western blot analysis. Data represent
the mean  S.E. of six independent experiments.
FIG. 7. mRNA expression of muscarinic receptor subtypes in
A-10 cells by RT-PCR. Total RNA prepared from either A-10 cells
(A10) or rat brain (rB, as positive control) was subjected to RT-PCR with
muscarinic receptor subtype-specific primers (m1, m2, m3, m4, and m5)
as described under “Experimental Procedures.” Elongation factor (EF-
1) was amplified under identical conditions as an internal control. The
PCR products were separated by 1.8% agarose gel electrophoresis and
stained with ethidium bromide and photographed.
FIG. 8. Effect of RGS5 ribozyme in enhancing AngII-stimu-
lated MAP kinase activity in RAOSMC. After transfection with
RGS-specific ribozymes (RZ3 and RZ5) or the corresponding inactive
ribozymes (RZ5m and RZ3m) in RAOSMC, cells were serum-starved for
48 h prior to stimulation with 1.0 nM AngII for 5 min at 72 h post-
transfection, harvested with 1 Sample Buffer, subjected to 12% SDS-
PAGE, and analyzed by Western blot as described under “Experimental
Procedures.” Both p42 and p44 were detected and showed similar re-
sponses, so the combined densities of the 42- and 44-kDa bands were
quantitated. The graph shows the mean  S.E. of pERK/ERK for four
independent experiments. The asterisk indicates that RGS5 ribozyme
produced a statistically significant (p  0.01) enhancement of AngII-
stimulated MAP kinase activity (AngII, black bars) compared with
AngII plus the inactive RGS5 ribozyme (AngII, white bars).
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regions on the template, ribozyme function also depends on the
presence of the GUC cleavage site. Thus a partial match be-
tween the ribozyme and a target RNA would not yield effective
degradation if the GUC were not present in the correct location.
A potential disadvantage of ribozymes over DNA antisense
oligonucleotides is the low stability of RNA in cells.
In this report, we describe the utility of a set of RGS ri-
bozymes. To avoid the rapid degradation in vivo (43), we used
chimeric DNA-RNA ribozymes and introduced phosphorothio-
ate linkages at the 3-end as reported previously (29, 44–46).
The 50% suppression of mRNA for RGS2, -3, -5, and -7 (Fig.
3, A and B), and protein for RGS3 (Fig. 4B) is quite substantial
given our transfection efficiency of about 50%. Thus, the mRNA
and protein appear to be almost completely suppressed in the
transfected population of cells. This compares favorably with
the recent report of RNAi-mediated inhibition in mammalian
cells that showed almost 100% suppression of protein expres-
sion from a co-transfected luciferase reporter with 70–90%
transfection efficiency (41). Furthermore, all four of the tested
ribozymes (RZ2, -3, -5, and -7) were effective in suppressing the
cognate RGS mRNA but did not suppress levels of other RGS
mRNAs. Because the first ribozyme designed for each RGS
worked, our findings suggest that stabilized ribozymes (i.e.
DNA-RNA chimers with phosphorothioation) should be a sim-
ple and robust strategy for reverse genetic studies of closely
related proteins in multimember families.
Role of Endogenous RGS Proteins in Specific Receptor Sig-
naling Pathways—Very few reports exist that detail the con-
tribution of endogenous RGS proteins to specific receptor re-
sponses. The use of RGS-insensitive G proteins (10, 47) has
revealed a prominent role for endogenous RGS proteins in
neuronal function in vitro (21, 48). This latter approach, how-
ever, blocks the function of all RGS proteins at the mutated G
subunit and thus cannot identify which specific RGS protein(s)
are involved. Two RGS “knockout” mouse strains have been
reported, RGS9 (22) and RGS2 (23). The former has prominent
alterations in the kinetics of the retinal photoresponse (known
to be mediated by the photon-receptor rhodopsin), and the
latter has immunologic and behavioral phenotypes (but the
underlying receptor system(s) remain undefined). The most
specific information to date has been derived from neutralizing
antibody studies of DRG neuron presynaptic neurotransmitter
signaling that show RGS4 and G interacting protein to have
differential effects on 2A-adrenergic receptor coupling to cal-
cium channel inhibition (49), whereas RGS12 seems to mediate
selectively the desensitization of -aminobutyric acid, type
B–receptor responses (24).
In this report, we show that endogenous RGS3 and RGS5 in
rat A-10 vascular smooth muscle cells and primary culture of
aorta smooth muscle cells have selective effects on MAP kinase
stimulation by muscarinic and angiotensin receptors. The ob-
servation that MAP kinase stimulation is enhanced when RGS
levels are reduced suggests that there is tonic (or rapidly in-
ducible) inhibition of these receptor responses by the endoge-
nous RGS proteins. RGS3 has been shown previously to regu-
late MAP kinase responses both in overexpression and
antisense knockdown studies (17). RGS5 overexpression, how-
ever, did not regulate MAP kinase activation induced by plate-
let-activating receptor (50). RGS5 is differentially expressed in
arterial smooth muscle compared with venous smooth muscle
(51). Thus the selectivity of RGS5 effects for angiotensin recep-
tors (this paper) and platelet-activating factor receptors (50) is
quite interesting in light of the limited tissue distribution of
RGS5 expression.
The RGS specificity observed here could be occurring at the
G protein level or may be dependent on receptor-RGS contacts
(direct or indirect). The muscarinic receptor response in A-10
cells seems to be mediated by the m3 subtype given the per-
tussis toxin insensitivity of the response and the abundance of
m3 muscarinic receptor message compared with m1 and m5
receptor transcripts. The m3 receptor is well known to activate
Gq/11 (38) but has also been reported recently (51) to activate
G12 or G13. In contrast, angiotensin receptors, which strongly
activate Gq/11 and Gi family members, do not appear to activate
G12 or G13 (53). The pertussis toxin insensitivity strongly im-
plicates Gq/11 for AT1a receptors, but the m3 response could be
either Gq/11- or G12/13-mediated. The former is more likely
because RhoA, which is activated by G12/13, is not considered to
be directly linked to ERK activation (54), whereas Gq/11-medi-
ated PKC activation can activate ERK by several mechanisms
(55). Also RGS3 has been reported not to be a GAP for G12
(16). For angiotensin receptor (AT1a), it has been reported that
it signals via both heterotrimeric G proteins (Gq/11) and non-
membrane tyrosine kinases (Jak2-STAT1) pathways that can
activate MAP kinase and induce IPx accumulation through
phospholipase C activation (33, 56–58). Thus, it appears that
both RGS3 and RGS5 are working through effects on Gq or G11
(Fig. 10), but the precise mechanism for receptor selectivity will
require additional study.
Concluding Remarks—These data show that endogenous
RGS3 is a negative modulator of ERK activation by endogenous
muscarinic m3 receptors mediated through a non-Gi/o, probably
Gq/11 pathway. At the same time, endogenous RGS5 is a neg-
ative modulator of AT1a receptor-mediated activation of ERK
FIG. 9. Effect of RGS5 ribozyme in enhancing angiotensin II-
stimulated IPx accumulation in RAOSMC. After transfection with
RGS-specific ribozymes (RZ3 and RZ5) or the corresponding inactive
ribozymes (RZ5m and RZ3m) in RAOSMC, cells were labeled with
[3H]myoinositol for 24 h and incubated with the indicated concentration
of AngII for 30 min. Inositol phosphates (IPx) were isolated and quan-
titated as described under “Experimental Procedures.” Data are mean
 S.E. of three AngII dose-response experiments. Values for IPx counts
in the presence of LiCl alone were subtracted from the angiotensin-
stimulated IPx release.
FIG. 10. Model of receptor-selectivity of RGS3 and RGS5
proteins.
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through a non-Gi/o, probably Gq/11, mechanism in both A-10
cells and primary culture of aorta smooth muscle cells. Thus we
demonstrate a novel receptor selectivity of RGS3 and RGS5
action in important signaling pathways in a differentiated cells
from vascular smooth muscle. The degree to which this conclu-
sion may be generalized to other signaling pathways and other
cell types is unclear and will depend on the precise mechanisms
that determine this selectivity. This study, however, is the first
to report such a clear receptor selectivity for endogenous RGS
proteins in which a given RGS preferentially regulates a given
receptor and provides useful tools, the stabilized ribozymes, to
permit the analysis of RGS function in a broader range of
cellular functions.
REFERENCES
1. Hepler, J. R., and Gilman, A. G. (1992) Trends Biochem. Sci. 17, 383–387
2. Birnbaumer, L. (1992) Cell 71, 1069–1072
3. Siderovski, D. P., Strockbine, B., and Behe, C. I. (1999) Crit. Rev. Biochem.
Mol. Biol. 34, 215–251
4. Berman, D. M., Wilkie, T. M., and Gilman, A. G. (1996) Cell 86, 445–452
5. De Vries, L., Zheng, B., Fisher, T., Elenko, E., and Farquhar, M. G. (2000)
Annu. Rev. Pharmacol. Toxicol. 40, 235–271
6. Ross, E. M and Wilkie, T. M. (2000) Annu. Rev. Biochem. 69, 795–827
7. Zheng, B., Ma, Y. C., Ostrom, R. S., Lavoie, C., Gill, G. N., Insel, P. A., Huang,
X. Y., and Farquhar, M. G. (2001) Science 294, 1939–1942
8. Heximer, S. P., Watson, N., Linder, M. E., Blumer, K. J., Hepler, J. R. (1997)
Proc. Natl. Acad. Sci. U. S. A. 94, 14389–14393
9. Hepler, J. R., Berman, D. M., Gilman, A. G., and Kozasa, T. (1997) Proc. Natl.
Acad. Sci. U. S. A. 94, 428–432
10. Lan, K. L., Zhong, H., Nanamori, M., and Neubig, R. (2000) J. Biol. Chem. 275,
33497–33503
11. Traver, S., Bidot, C., Spassky, N., Baltauss, T., De Tand, M. F., Thomas, J. L.,
Zalc, B., Janoueix-Lerosey, I., and Gunzburg, J. D. (2000) Biochem. J. 350,
19–29
12. Hepler, J. R. (1992) Trends Pharmacol. Sci. 20, 376–382
13. Zheng, B., De Vries, L., and Farquhar, M. G. (1999) Trends Biochem. Sci. 24,
411–414
14. Seki, N., Sugano, S., Suzuki, Y., Nakagawara, A., Ohira, M., Muramatsu, M.,
Saito, T., and Hori, T. (1998) Hum. Genet. 43, 202–205
15. Zhou, J., Moroi, K., Nishiyama, M., Usui, H., Seki, N., Ishida, J., Fukamizu, A.,
and Kimura, S. (2001) Life Sci. 68, 1457–1469
16. Scheschonka, A., Dessauer, C. W., Sinnarajah, S., Chidiac, P., Shi, C. S., and
Kehrl, J. H. (2000) Mol. Pharmacol. 58, 719–728
17. Dulin, N. O., Sorokin, A., Reed, E., Elliott, S., Kehrl, J. H., and Dunn, M. J.
(1999) Mol. Cell. Biol. 19, 714–723
18. Neill, J. D., Duck, L. W., Sellers, J. C., Musgrove, L. C., Scheschonka, A.,
Druey, K. M., and Kehrl, J. N. (1997) Endocrinology 138, 843–846
19. Zeng, W., Xu, X., Popov, S., Mukhopadhyay, S., Chidiac, P., Yagaloff, K. A.,
Fisher, S. L., Ross, E. M., Muallem, S., and Wilkie, T. M. (1998) J. Biol.
Chem. 273, 34687–34690
20. Snow, B. E., Hall, R. A., Krumins, A. M., Brothers, G. M., Bouchard, D.,
Brothers, C. A., Chung, S., Mangion, J., Gilman, A. G., Lefkowitz, R. J., and
Siderovski, D. P. (1998) J. Biol. Chem. 273, 17749–17755
21. Jeong, S. W., and Ikeda, S. R. (2000) J. Neurosci. 20, 4489–4496
22. Chen, C. K., Burns, M. E., He, W., Wensel, T. G., Baylor, D. A., and Simon,
M. I. (2000) Nature 403, 557–560
23. Oliveira-dos-Santos, A. J., Matsumoto, G., Snow, B. E., Bai, D., Houston, F. P.,
Whishaw, I. Q., Mariathasan, S., Sasaki, T., Wakeham, A., Ohashi, P. S.,
Roder, J. C., Barnes, C. A., Siderovski, D. P., and Penninger, J. M. (2000)
Proc. Natl. Acad. Sci. U. S. A. 97, 12272–12277
24. Schiff, M. L., Siderovski, D. P., Jordan, J. D., Brothers, G., Snow, B., De Vries,
L., Ortiz, D. F., and Diverse-Pierluissi, M., (2000) Nature 408, 723–727
25. Alexander, R. W., and Griendling, K. K. (1996) J. Hypertens. 14, S51–S54
26. Yalkinoglu, 	.
., Spreyer, P., Bechem, M., Apeler, H., and Wohlfeil, S. (1995)
J. Recept. Signal. Transduct. Res. 15, 117–130
27. Touyz, R. M., and Schiffrin, E. L. (1996) J. Biol. Chem. 271, 24353–24358
28. Benjamin, C. W., Linseman, D. A., and Jones, D. A. (1994) J. Biol. Chem. 269,
31346–31349
29. Wang, Q., Mullah, B., Hansen, C., Asundi, J., and Robishaw, J. D. (1997)
J. Biol. Chem. 272, 26040–26048
30. Wang, Q., Jolly, J. P., Surmeier, J. D., Mullah, B., Lidow, M. S., Bergson, C. M.,
and Robishaw, J. D. (2001) J. Biol. Chem. 276, 39386–39393
31. Grassi, G., Forlino, A., and Marini, J. C. (1997) Nucleic Acids Res. 25,
3451–3458
32. Dudley, D. T., Panek, R. L., Major, T. C., Lu, G. H., Bruns, R. F., Klinkefus,
B. A., Hodges, J. C., and Weishaar, R. E. (1990) Mol. Pharmacol. 38,
370–377
33. Seta, K., Nanamori, M., Modral, J. G., Neubig, R. R., and Sadoshima, J. (2002)
J. Biol. Chem. 277, 9268–9277
34. Grant, S. L., Lassegue, B., Griendling, K. K., Ushio-Fukai, M., Lyons, P. R.,
and Alexander, R. W. (2000) Mol. Pharmacol. 57, 460–467
35. Kardestuncer, T., Wu, H., Lim, A. L., and Neer, E. J. (1998) FEBS Lett. 438,
285–288
36. Chattejee, T. K., Eapen, A. K., and Fisher, R. A. (1997) J. Biol. Chem. 272,
15481–15487
37. Druey, K. M., Blumer, K. J., Kang, V. H., and Kehrl, J. U. (1996) Nature 379,
742–746
38. Caulfield, M. P., and Birdsall, N. J. M., (1998) Pharmacol. Rev. 50, 279–290
39. Dohlman, H. G., Song, J., Ma, D., Courchesne, W. E., and Thorner, J. (1996)
Mol. Cell. Biol. 16, 5194–5209
40. Zhong, H. L., and Neubig, R. R. (2001) J. Pharmacol. Exp. Ther. 297, 837–845
41. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A, Weber, K., and Tuschl,
T. (2001) Nature 411, 494–498
42. Garzon, J., Rodriguez-Diaz, M., Lopez-Fando, A., and Sanchez-Blazquez, P.
(2001) Eur. J. Neurosci. 13, 801–811
43. Heidenreich, O., and Eckstein, F. (1992) J. Biol. Chem. 267, 1904–1909
44. Gu, J., Veerapanane, D., Rossi, J., Natarajan, R., Thomas, L., and Nadler, J.
(1995) Circ. Res. 77, 14–20
45. Shimayama, T., Nishikawa, F., Nishikawa, S., and Taira, K. (1993) Nucleic
Acids Res. 21, 2605–2611
46. Taylor, N., Kaplan, B., Swiderski, P., Haitang, L., and Rossi, J. (1992) Nucleic
Acids Res. 20, 4559–4565
47. DiBello, P. R., Garrison, T. R., Apanovitch, D. M., Hoffman, G., Shuey, D. J.,
Mason, K., Cockett, M. I., and Dohlman, H. G. (1998) J. Biol. Chem. 273,
5780–5784
48. Chen, H., and Lambert, N. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97,
12810–12815
49. Diverse-Pierluissi, M., Fischer, T., Jordan, J. D., Schiff, M. L., Ortiz, D. F.,
Farquhar, M. G., and De Vries, L. (1999) J. Biol. Chem. 274, 14490–14494
50. Zhang, Y., Neo, S. Y., Han, J., Yaw, L. P., and Lin, S. C. (1999) J. Biol. Chem.
274, 2851–2857
51. Adams, L. D., Geary, R. L., McManus, B., and Schawrtz, S. M. (2000) Circ. Res.
87, 623–631
52. Rumenapp, U., Asmus, M., Schablowski, H., Woznicki, M., Han, L., Jakobs,
K. H., Fahimi-Vahid, M., Michalek, C., Wieland, T., and Schmidt, M. (2001)
J. Biol. Chem. 276, 2474–2479
53. Gohla, A., Offermanns, S., Wilkie, T. M., and Schultz, G. (1999) J. Biol. Chem.
274, 17901–17907
54. Whitehead, I. P., Zohn, I. E., and Der, C. J. (2001) Oncogene 20, 1547–1555
55. Gutkind, J. S. (1998) J. Biol. Chem. 273, 1839–1842
56. Schorb, W., Peeler, T. C., Madigan, N. N., Conrad, K. M., and Baker, K. M.
(1994) J. Biol. Chem. 269, 19626–19632
57. Sadoshima, J., Qiu, Z. H., Morgan, J. P., and Izumo, S. (1995) Circ. Res. 76,
1–15
58. Doan, T. N., Showkat Ali, M., and Bernstein, K. E. (2001) J. Biol. Chem. 276,
20954–20958
Receptor-selective Regulation of MAP Kinase by RGS3 and RGS524958
